Abstracts tagged "Intervention"

Abstract Number: 1861 • ACR Convergence 2023
Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Eduardo Santos¹, Bayram Farisogullari², Emma Dures³, Rinie Geenen⁴ and Pedro Machado⁵, ¹Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁴Utrecht University, Vorstenbosch, Netherlands, ⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: To identify the best evidence on the efficacy of non-pharmacological interventions in reducing fatigue in people with I-RMDs and to summarise their safety in…
Abstract Number: 0013 • ACR Convergence 2023
A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients
Mehreen Elahee¹, Kathryne Marks², Ifeoluwakiisi Adejoorin², Lin Chen², Derrick Todd², Jonathan Coblyn², Elena Massarotti², Susan Ritter², Michael Weinblatt³, Daniel Solomon⁴ and Deepak Rao², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Waban, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: There are multiple DMARDs available to treat rheumatoid arthritis (RA) yet there are no widely used predictive biomarkers to guide selection of a specific…
Abstract Number: 2580 • ACR Convergence 2023
High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis
Kasper Jensen¹, Per Aagaard², Charlotte Suetta³, Jakob Nielsen², Rune Bech⁴, Henrik Schrøder¹, Casper Simonsen¹, Jan Christensen¹ and Louise Pyndt Diederichsen⁵, ¹University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark, ²University of Southern Denmark, Odense, Denmark, ³Bispebjerg Hospital, Copenhagen, Denmark, ⁴Zealand University Hospital, Koege, Dragør, Denmark, ⁵University Hospital of Copenhagen, Rigshospitalet, Dragør, Denmark
Background/Purpose: Myositis is associated with muscle impairment, which impacts quality of life. The purpose of this study was to investigate the effects of high-intensity strength…
Abstract Number: 0317 • ACR Convergence 2023
Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein¹, Marike Van der Leeden², Martijn Gerritsen², Jos W.R. Twisk¹, Martin van der Esch², Henriët van Middendorp³, Peter Weijs⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Reade Rheumatology Center, Amsterdam, Netherlands, ³Leiden University, Leiden, Netherlands, ⁴Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced The Western…
Abstract Number: 2596 • ACR Convergence 2023
Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database
Qingran Yan¹, Cosimo Bruni², Alexandru Garaiman², Carina Mihai², Suzana Jordan², Mike Becker³, Muriel Elhai⁴, Rucsandra Dobrota², liubov Petelytska³, Anna-Maria Hoffmann-Vold⁵, Joerg Henes⁶, Eric Hachulla⁷, Elise Siegert⁸, Alexandra Balbir-Gurman⁹, Giovanna Cuomo¹⁰, Gabriela Riemekasten¹¹, Stefan Heitmann¹², valeria Riccieri¹³, Susanne Ullman¹⁴, Petros Sfikakis¹⁵, Francesca Ingegnoli¹⁶, Vera Bernardino¹⁷, Marie-Elise Truchetet¹⁸, Francesco Del Galdo¹⁹, SHUANG YE²⁰ and Oliver Distler², ¹Department of Rheumatology, University Hospital Zurich, Zurich, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴University Hospital zurich, University of Zurich, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶University Hospital Tuebingen, Tuebingen, Germany, ⁷University of Lille, Lille, France, ⁸Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ¹¹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹²Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, ¹³Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, ¹⁴Department of Dermatology, University Hospital of Copenhagen, Hospital Bispebjerg, Copenhagen, Denmark, ¹⁵National Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁶Universita' degli Studi di Milano, Milano, Italy, ¹⁷Centro Hospitalar Lisboa Central, Lisbon, Portugal, ¹⁸Bordeaux University Hospital, Bordeaux, France, ¹⁹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ²⁰Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) with the current best evidence for the treatment of systemic…
Abstract Number: 0328 • ACR Convergence 2023
From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Marc Blanchard¹, Pedro Ming Azevedo², Tiffany Prétat², Cinja Koller² and Thomas Hügle³, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ²Lausanne University Hospital, Lausanne, Switzerland, ³Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: Post-viral fibromyalgia is a chronic condition that can develop in individuals following a viral infection, such as COVID-19. Recent studies have shown that approximately…
Abstract Number: 2597 • ACR Convergence 2023
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis and Lower Gastrointestinal Tract Symptoms: Data from the ReSScue Phase 2 Randomized Clinical Trial
Anna-Maria Hoffmann-Vold¹, Havard Fretheim¹, Imon Barua¹, Maylen Nordgård Carstens¹, Henriette Didriksen², Vikas Sarna¹, Knut AE Lundin¹, Oliver Distler³, Dinesh Khanna⁴, Elizabeth Volkmann⁵, Oyvind Midtvedt¹, Tore Midtvedt⁶, Alvilde Dhainaut⁷, Anne-Kristine H Halse⁸, Gunnstein Bakland⁹, Inge Olsen¹, Maiju E Pesonen¹ and Oyvind Molberg¹⁰, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Moss, Norway, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Michigan, Ann Arbor, MI, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷St. Olav, Trondheim, Norway, ⁸University Hospital Bergen, Bergen, Norway, ⁹University Hospital of North Norway, Tromsø, Norway, ¹⁰Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Lower gastrointestinal tract (GIT) complications are common in patients with systemic sclerosis (SSc), associate with a high disease burden, and current treatment alternatives are…
Abstract Number: 0063 • ACR Convergence 2022
Implementability of a SLE Medication Adherence Intervention
Kai Sun¹, Nneka Molokwu², Amy Corneli¹, Kathryn Pollak¹, Alexandria Bennion², Jennifer L Rogers³, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Amanda Eudy⁴, Hayden Bosworth¹ and Megan Clowse², ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC, ⁴Duke University, Raleigh, NC
Background/Purpose: Medication nonadherence in SLE is common and negatively impacts patient outcomes. Yet, little is known about how to improve medication adherence in patients with…
Abstract Number: 0126 • ACR Convergence 2022
Should Arthrocentesis Be Attempted in the Symptomatic but Non-Effusive Knee?
Rosemina Patel¹, Angie Ariza-hutchinson¹, Ahsan Iqbal¹, Matthew McElwee¹, N. Suzanne Emil¹, Sharon Nunez¹, maheshwari muruganandam¹, frank O'Sullivan¹, Roderick Fields¹, Yvonne Waters² and Wilmer Sibbitt¹, ¹University of New Mexico, Albuquerque, NM, ²University of New Mexico Hospital, Corrales, NM
Background/Purpose: Arthrocentesis of the painful but non-effusive knee is usually not undertaken due to a high arthrocentesis failure rate. We hypothesized that compression-assisted arthrocentesis of…
Abstract Number: 0173 • ACR Convergence 2022
Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis
Victoria Werth¹, Barbara White², Josef Concha³, Josh Dan¹, Nancy Dgetluck², Kathleen Hally², Scott Constantine², Rohit Aggarwal⁴, David Fiorentino⁵, Ingrid Lundberg⁶ and Chester Oddis⁷, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Corbus Pharmaceuticals, Norwood, MA, ³Universiity of Pennsylvania/Dermatology, Philadelphia, PA, ⁴University of Pittsburgh, Division of Rheumatology, Pittsburgh, PA, ⁵Stanford university/Department of Dermatology, Palo Alto, CA, ⁶Karolinska Institute, Stockholm, Sweden, ⁷University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Safe and effective treatments are of significant unmet need in DM. Lenabasum, a CB2 agonist that activates resolution of inflammation, improved skin disease, patient-reported…
Abstract Number: 0201 • ACR Convergence 2022
Real-World Evidence from Social Media Provides Insights into Patient Mental Health Outcomes in the Management of Gout
Maurice Flurie¹, Joseph Coe², Monica Converse¹, Kristina Davidson³, Colton Flowers¹, Kelly Gavigan⁴, Daniel Hernandez⁵, Helen Hernandez¹, Gary Ho⁶, Brian LaMoreaux³, Christopher Parker⁶, E. Robert Wassman¹, Christopher DeFelice¹ and Maria Picone¹, ¹TREND Community, Philadelphia, ²Global Healthy Living Foundation, Upper Nyack, ³Horizon Therapeutics, Chicago, IL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Gout Support Group of America, Austin, TX
Background/Purpose: The ability to actively listen to and interpret the patient experience is vital to effectively address the needs of individuals within a particular community.…
Abstract Number: 0571 • ACR Convergence 2022
National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Anna Montgomery¹, Gary Tarasovsky², Mary Whooley², Jennifer Barton³, Karla Miller⁴, Holly Mitchell⁵, Jo Dana², Kimberly Reiter⁶, Elizabeth Wahl⁷, Karine Rozenberg-Ben-Dror⁸, Jing Li⁹ and Gabriela Schmajuk¹⁰, ¹University of California San Francisco, Reno, NV, ²San Francisco VA Medical Center, San Francisco, CA, ³VA Portland Health Care System/OHSU, Portland, OR, ⁴University of Utah Division of Rheumatology/VA Salt Lake City Health Care, Salt Lake City, UT, ⁵Ralph H. Johnson VA Hospital, Mount Pleasant, SC, ⁶Albuquerque VA Medical Center, Albuquerque, NM, ⁷VA Puget Sound Healthcare System, Seattle, WA, ⁸Greater Lakes Region/VISN 12 Dept Veterans Affairs, Hines, IL, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰UCSF / SFVA, San Francisco, CA
Background/Purpose: Guidelines recommend testing for latent hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB) infection prior to initiating biologics or targeted synthetic…
Abstract Number: 1269 • ACR Convergence 2022
Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
Sancia Ferguson¹, Lori Zemlicka², Amanda Weber², Abdul Halabi³, Jon Arnason⁴ and Christie Bartels⁵, ¹University of Wisconsin School of Medicine & Public Health, Madison, WI, ²UW Health, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin Hospitals and Clinics, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: The treat-to-target approach endorsed by the ACR for rheumatoid arthritis requires frequent monitoring of disease activity using validated instruments, with changes to the treatment…
Abstract Number: 1809 • ACR Convergence 2022
Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial
Keigo Hayashi¹, yuqing zhang², Hyon Choi³ and Kazuki Yoshida⁴, ¹Brigham and Women's Hospital, Okayama, Japan, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Low-dose colchicine has been demonstrated to reduce cardiovascular (CV) events in two recent large cardiovascular trials. Gout patients, for whom colchicine is a highly relevant…
Abstract Number: 2003 • ACR Convergence 2022
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
Malin Erlandsson¹, Karin Andersson¹, Sofia Töyrä Silfverswärd², Rille pullerits² and Maria Bokarewa², ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Combination of IFN-stimulated genes known as IFN signature, helps to predict disease activity and treatment response in several autoimmune diseases, including rheumatoid arthritis (RA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].